Analytical Data
-
Gene name
IL28B
- Application
-
Alternative Names
IL28B；IL28B；IL28C；ZCYTO22；Interferon lambda-3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8IZI9
-
Expression Region
1-196aa
-
AA Sequence
MTGDCMPVLV LMAAVLTVTG AVPVARLRGA LPDARGCHIA QFKSLSPQEL QAFKRAKDAL EESLLLKDCK CRSRLFPRTW DLRQLQVRER PVALEAELAL TLKVLEATAD TDPALGDVLD QPLHTLHHIL SQLRACIQPQ PTAGPRTRGR LHHWLHRLQE APKKESPGCL EASVTFNLFR LLTRDLNCVA SGDLCV
-
Molecular Weight
21 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IL28B, also known as Interleukin-28B, is a member of the interferon lambda family and plays a crucial role in the immune response against viral infections. Its significance has gained attention particularly in the context of hepatitis C virus (HCV) infection, where genetic variations in the IL28B gene have been associated with differential responses to antiviral therapies, such as pegylated interferon and ribavirin. Individuals carrying specific single nucleotide polymorphisms (SNPs) in the IL28B gene demonstrate varying degrees of viral clearance, making IL28B a key factor in predictive medicine for HCV treatment. Research on recombinant IL28B protein aims to explore its potential therapeutic applications and mechanism of action in enhancing the antiviral response. High-throughput studies have indicated that the recombinant protein exhibits potent antiviral activity, potentially by modulating the activation of immune cells and enhancing the production of downstream interferons. Understanding the structure-function relationship of IL28B and its interaction with specific receptors is essential for developing novel therapeutic strategies. Additionally, investigations into its role in other viral infections, like HIV and influenza, are expanding the scope of IL28B research. Thus, the development and characterization of IL28B recombinant protein not only enhance our understanding of its biological functions but may also lead to improved treatment options for various viral diseases through precision medicine approaches.
